Secreted Frizzled Related Protein‑2 (sFRP‑2) belongs to a family of Wnt‑binding proteins with homology to the ligand‑binding domain of the Frizzled transmembrane Wnt receptors. The sFRP proteins are approximately 30‑35 kDa in size and contain an N-terminal Frizzled‑like domain with 10 conserved cysteines and a Netrin‑like C‑terminal domain (1, 2). Mature human sFRP‑2, also known as SARP‑1, SDF‑5, and FRP‑2, shares 99% aa sequence identity with mouse and rat sFRP‑2 (3). sFRP‑2 is widely expressed during embryogenesis and in the adult tissues including the eye, heart, lung, colon, intestine, smooth muscle, pancreas, prostate, testis, kidney, brain, teeth and joints, craniofacial mesenchyme, and preadipocytes (3‑6). Depending on the context, sFRP‑2 can exert either positive or negative effects on Wnt signaling (7‑9). It also inhibits BMP‑induced effects (8, 10). sFRP‑2 can be incorporated into the extracellular matrix through interactions with Fibronectin and Integrin alpha 5 beta 1 (11). sFRP‑2 plays a variety of roles during tissue morphogenesis including inhibition of the planar cell polarity pathway and myoblast and osteoblast differentiation (8, 10, 12, 13). sFRP‑2 is also expressed in multiple myeloma and glioma in which it promotes tumorigenicity (10, 14). At physiological concentrations sFRP‑2 enhances BMP‑1 mediated proteolysis of Pro‑Collagen I, whereas at higher concentrations it inhibits BMP‑1 activity (15, 16). This difference is significant considering that sFRP‑2 is up‑regulated in fibrotic areas of the heart following myocardial infarction (15, 16). Elevated levels of sFRP‑2 then promote the recovery of cardiac function by reducing collagen deposition, remodeling, and calcification and by promoting the engraftment of mesenchymal stem cells into the heart (8, 15).